ReNeuron Group plc (LON:RENE – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 4.12 ($0.05) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares traded.
ReNeuron Group Stock Performance
The firm has a market capitalization of £1.93 million, a PE ratio of -37.50 and a beta of 0.69. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25. The business’s 50 day simple moving average is GBX 3.38 and its two-hundred day simple moving average is GBX 4.10.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Recommended Stories
- Five stocks we like better than ReNeuron Group
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 4/22 – 4/26
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the NASDAQ Stock Exchange?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
